Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
13.81
+0.22 (1.62%)
Oct 30, 2025, 3:30 PM EDT - Market open
Surrozen Revenue
Surrozen had revenue of $983.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $12.62M. In the year 2024, Surrozen had annual revenue of $10.66M.
Revenue (ttm)
$12.62M
Revenue Growth
n/a
P/S Ratio
5.03
Revenue / Employee
$307,829
Employees
41
Market Cap
118.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.66M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 12.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
SRZN News
- 7 weeks ago - Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Surrozen to Present at Upcoming Healthcare Investor Conference - GlobeNewsWire
- 2 months ago - Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - GlobeNewsWire
- 6 months ago - Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 7 months ago - Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - GlobeNewsWire
- 1 year ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire